Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 157 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Gilteritinib maintenance therapy for FLT3-ITD mutated acute myeloid leukaemia	Gilteritinib (ASP2215; Xospata; gilteritinib fumarate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2022	View \| Download
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line	Gilteritinib (ASP2215; Xospata; gilteritinib fumarate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Futibatinib for treating cholangiocarcinoma with FGFR2 gene rearrangements	Futibatinib	Cholangiocarcinoma	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Fedratinib for Myelofibrosis	Fedratinib (SAR302503)	Myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2018	View \| Download
Favezelimab-Pembrolizumab for treating relapsed or refractory classical Hodgkin Lymphoma after 2 or more therapies	Favezelimab-pembrolizumab	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Erdafitinib for treating advanced solid tumours with an FGFR mutation in people aged 6 years and older	Erdafitinib (JNJ-42756493; BALVERSA)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download
Epcoritamab for treating relapsed or refractory follicular lymphoma	Epcoritamab (GEN-3013)	Follicular lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma previously treated with at least one line of systemic therapy	Epcoritamab (GEN-3013)	B-cell non-Hodgkin lymphoma	Haematological Cancer and Lymphomas	2024	View \| Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments	Epcoritamab (GEN-3013)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients	Entrectinib (RXDX-101)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2018	View \| Download